These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35662813)

  • 1. Lentiviral gene therapy prevents anti-human acid α-glucosidase antibody formation in murine Pompe disease.
    Liang Q; Vlaar EC; Catalano F; Pijnenburg JM; Stok M; van Helsdingen Y; Vulto AG; Unger WWJ; van der Ploeg AT; Pijnappel WWMP; van Til NP
    Mol Ther Methods Clin Dev; 2022 Jun; 25():520-532. PubMed ID: 35662813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease.
    Douillard-Guilloux G; Richard E; Batista L; Caillaud C
    J Gene Med; 2009 Apr; 11(4):279-87. PubMed ID: 19263466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance.
    Sun B; Bird A; Young SP; Kishnani PS; Chen YT; Koeberl DD
    Am J Hum Genet; 2007 Nov; 81(5):1042-9. PubMed ID: 17924344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy.
    Liang Q; Catalano F; Vlaar EC; Pijnenburg JM; Stok M; van Helsdingen Y; Vulto AG; van der Ploeg AT; van Til NP; Pijnappel WWMP
    Mol Ther Methods Clin Dev; 2022 Dec; 27():109-130. PubMed ID: 36284764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction.
    Han SO; Ronzitti G; Arnson B; Leborgne C; Li S; Mingozzi F; Koeberl D
    Mol Ther Methods Clin Dev; 2017 Mar; 4():126-136. PubMed ID: 28344998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
    Cousens LP; Mingozzi F; van der Marel S; Su Y; Garman R; Ferreira V; Martin W; Scott DW; De Groot AS
    Hum Vaccin Immunother; 2012 Oct; 8(10):1459-64. PubMed ID: 23095864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lentiviral Hematopoietic Stem Cell Gene Therapy Rescues Clinical Phenotypes in a Murine Model of Pompe Disease.
    Piras G; Montiel-Equihua C; Chan YA; Wantuch S; Stuckey D; Burke D; Prunty H; Phadke R; Chambers D; Partida-Gaytan A; Leon-Rico D; Panchal N; Whitmore K; Calero M; Benedetti S; Santilli G; Thrasher AJ; Gaspar HB
    Mol Ther Methods Clin Dev; 2020 Sep; 18():558-570. PubMed ID: 32775491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lentiviral Hematopoietic Stem Cell Gene Therapy Corrects Murine Pompe Disease.
    Stok M; de Boer H; Huston MW; Jacobs EH; Roovers O; Visser TP; Jahr H; Duncker DJ; van Deel ED; Reuser AJJ; van Til NP; Wagemaker G
    Mol Ther Methods Clin Dev; 2020 Jun; 17():1014-1025. PubMed ID: 32462050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease.
    Sun B; Banugaria SG; Prater SN; Patel TT; Fredrickson K; Ringler DJ; de Fougerolles A; Rosenberg AS; Waldmann H; Kishnani PS
    Mol Genet Metab Rep; 2014; 1():446-450. PubMed ID: 27896120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.
    Su J; Sherman A; Doerfler PA; Byrne BJ; Herzog RW; Daniell H
    Plant Biotechnol J; 2015 Oct; 13(8):1023-32. PubMed ID: 26053072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
    Han SO; Li S; Bird A; Koeberl D
    Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review.
    Desai AK; Li C; Rosenberg AS; Kishnani PS
    Ann Transl Med; 2019 Jul; 7(13):285. PubMed ID: 31392197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade.
    Han SO; Li S; Brooks ED; Masat E; Leborgne C; Banugaria S; Bird A; Mingozzi F; Waldmann H; Koeberl D
    Hum Gene Ther; 2015 Jan; 26(1):26-35. PubMed ID: 25382056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening chimeric GAA variants in preclinical study results in hematopoietic stem cell gene therapy candidate vectors for Pompe disease.
    Dogan Y; Barese CN; Schindler JW; Yoon JK; Unnisa Z; Guda S; Jacobs ME; Oborski C; Maiwald T; Clarke DL; Schambach A; Pfeifer R; Harper C; Mason C; van Til NP
    Mol Ther Methods Clin Dev; 2022 Dec; 27():464-487. PubMed ID: 36419467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory, liver depot gene therapy for Pompe disease.
    Bond JE; Kishnani PS; Koeberl DD
    Cell Immunol; 2019 Aug; 342():103737. PubMed ID: 29295737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease.
    Sun B; Li S; Bird A; Yi H; Kemper A; Thurberg BL; Koeberl DD
    J Gene Med; 2010 Nov; 12(11):881-91. PubMed ID: 20967919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.
    Prater SN; Patel TT; Buckley AF; Mandel H; Vlodavski E; Banugaria SG; Feeney EJ; Raben N; Kishnani PS
    Orphanet J Rare Dis; 2013 Jun; 8():90. PubMed ID: 23787031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
    Messinger YH; Mendelsohn NJ; Rhead W; Dimmock D; Hershkovitz E; Champion M; Jones SA; Olson R; White A; Wells C; Bali D; Case LE; Young SP; Rosenberg AS; Kishnani PS
    Genet Med; 2012 Jan; 14(1):135-42. PubMed ID: 22237443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
    Han SO; Pope R; Li S; Kishnani PS; Steet R; Koeberl DD
    Mol Genet Metab; 2016 Feb; 117(2):114-9. PubMed ID: 26454691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.